MAT2203 + Amphotericin B
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cryptococcal Meningitis
Conditions
Cryptococcal Meningitis
Trial Timeline
Oct 24, 2019 → Feb 15, 2023
NCT ID
NCT04031833About MAT2203 + Amphotericin B
MAT2203 + Amphotericin B is a phase 1/2 stage product being developed by Matinas Biopharma for Cryptococcal Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04031833. Target conditions include Cryptococcal Meningitis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05541107 | Phase 3 | UNKNOWN |
| NCT04031833 | Phase 1/2 | Completed |
Competing Products
18 competing products in Cryptococcal Meningitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine | Novartis | Phase 2 | 52 |
| Mycograb + placebo | Novartis | Phase 2 | 52 |
| Single dose liposomal Amphotericin and Fluconazole + Fluconazole | Gilead Sciences | Phase 2/3 | 64 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Fluconazole + Amphotericin B | Pfizer | Phase 3 | 76 |
| Flucytosine + Fluconazole + Amphotericin B | Pfizer | Pre-clinical | 22 |
| Fluconazole | Pfizer | Pre-clinical | 22 |
| Lobradimil + Amphotericin B | Alkermes | Phase 1 | 30 |
| Flucytosine and fluconazole + Fluconazole | Bausch Health | Phase 2 | 47 |
| Encochleated Amphotericin B | Matinas Biopharma | Phase 1/2 | 33 |
| MAT2203 + Amphotericin B | Matinas Biopharma | Phase 3 | 69 |